[go: up one dir, main page]

CA2190293C - Methode de traitement des cancers par regulation de la proteine p53 - Google Patents

Methode de traitement des cancers par regulation de la proteine p53 Download PDF

Info

Publication number
CA2190293C
CA2190293C CA2190293A CA2190293A CA2190293C CA 2190293 C CA2190293 C CA 2190293C CA 2190293 A CA2190293 A CA 2190293A CA 2190293 A CA2190293 A CA 2190293A CA 2190293 C CA2190293 C CA 2190293C
Authority
CA
Canada
Prior art keywords
glu
lys
ser
asp
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2190293A
Other languages
English (en)
French (fr)
Other versions
CA2190293A1 (fr
Inventor
Serge Carillo
Jean-Marie Blanchard
Marc Peichaczyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of CA2190293A1 publication Critical patent/CA2190293A1/fr
Application granted granted Critical
Publication of CA2190293C publication Critical patent/CA2190293C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2190293A 1994-05-31 1995-05-22 Methode de traitement des cancers par regulation de la proteine p53 Expired - Fee Related CA2190293C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR94/06583 1994-05-31
FR9406583A FR2720277B1 (fr) 1994-05-31 1994-05-31 Méthode de traitement des cancers par régulation de la protéine P53.
PCT/FR1995/000670 WO1995033060A1 (fr) 1994-05-31 1995-05-22 Methode de traitement des cancers par regulation de la proteine p53

Publications (2)

Publication Number Publication Date
CA2190293A1 CA2190293A1 (fr) 1995-12-07
CA2190293C true CA2190293C (fr) 2011-06-28

Family

ID=9463670

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2190293A Expired - Fee Related CA2190293C (fr) 1994-05-31 1995-05-22 Methode de traitement des cancers par regulation de la proteine p53

Country Status (8)

Country Link
EP (1) EP0763121A1 (sv)
JP (1) JPH10500978A (sv)
AU (1) AU714209B2 (sv)
CA (1) CA2190293C (sv)
FI (1) FI120501B (sv)
FR (1) FR2720277B1 (sv)
NO (1) NO321411B1 (sv)
WO (1) WO1995033060A1 (sv)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518488C1 (de) * 1995-05-19 1996-10-10 Progen Biotechnik Gmbh Autoantigen, geeignet zur Feststellung einer Thromboseneigung
EP0799892A3 (en) * 1996-04-05 1998-08-12 Takeda Chemical Industries, Ltd. Calpain, its production and use
US6232454B1 (en) 1998-02-27 2001-05-15 Incyte Genomics, Inc. Human proteinase molecules
AU2344100A (en) * 1998-11-18 2000-06-05 Canji, Inc. Viral vectors with late transgene expression
AU2001247922A1 (en) * 2000-03-31 2001-10-15 Parker Hughes Institute Calpain inhibitors in cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753665B2 (ja) * 1984-04-20 1995-06-07 財団法人癌研究会 抗転移剤
US5340922B1 (en) * 1988-05-31 1999-11-02 Mclean Hospital Corp Neural calcium-activated neutral proteinase inhibitors
EP0395309B1 (en) * 1989-04-28 1995-12-27 Takara Shuzo Co. Ltd. Human calpastatin-like polypeptide
JPH0641067A (ja) * 1992-04-20 1994-02-15 Kitasato Inst:The 新規カルパイン阻害物質ｋｐ−１２４１及びその製造法
EP0580161A1 (en) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Prophylactic and therapeutic treatment of Alzheimer's disease
US5607831A (en) * 1993-03-25 1997-03-04 The United States Of America As Represented By The Department Of Health And Human Services In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death

Also Published As

Publication number Publication date
FI120501B (sv) 2009-11-13
FI964783A0 (sv) 1996-11-29
FR2720277A1 (fr) 1995-12-01
EP0763121A1 (fr) 1997-03-19
AU714209B2 (en) 1999-12-23
WO1995033060A1 (fr) 1995-12-07
CA2190293A1 (fr) 1995-12-07
NO321411B1 (no) 2006-05-08
FI964783L (sv) 1996-11-29
JPH10500978A (ja) 1998-01-27
FR2720277B1 (fr) 1996-07-12
NO964772L (no) 1996-11-11
NO964772D0 (no) 1996-11-11
AU2620695A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
CA2163256C (fr) Vecteurs adenoviraux d'origine animale et utilisation en therapie genique
CA2228667C (fr) Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
FR2732357A1 (fr) Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
FR2712603A1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
CA2184841C (fr) Adenovirus recombinants codant pour le facteur neurotrophique des cellules gliales (gdnf)
CA2197235C (fr) Adenovirus comprenant un gene codant pour la glutathion peroxydase
EP0719328B1 (fr) Gene grb3-3, ses variants et leurs utilisations
WO1996010087A1 (fr) Methode de traitement des cancers par regulation de l'activite des proteines ras
CA2190293C (fr) Methode de traitement des cancers par regulation de la proteine p53
CA2268865C (fr) Fragments d'anticorps a chaine unique anti-p53 et utilisations
FR2746110A1 (fr) Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
FR2731710A1 (fr) Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
WO1997028186A1 (fr) PROTEINE PURIFIEE SR-p70
CA2197904A1 (fr) Adenovirus recombinants defectifs avec un gene iva2 inactive
FR2722507A1 (fr) Adenovirus comportant un gene codant pour une no synthase
CA2173338C (fr) Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodegeneratives
FR2734826A1 (fr) Deltap62, ses variants, sequences nucleiques et leurs utilisations
US20030060435A1 (en) Method of cancer treatment by p53 protein control
WO1995022616A1 (fr) Modele animal de la maladie d'alzheimer, preparation et utilisations
MXPA96005522A (en) Method for the treatment of cancer through the control of protein
CA2343922A1 (fr) Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150522